Literature DB >> 18373987

Treatment disparities for disabled medicare beneficiaries with stage I non-small cell lung cancer.

Lisa I Iezzoni1, Long H Ngo, Donglin Li, Richard G Roetzheim, Reed E Drews, Ellen P McCarthy.   

Abstract

UNLABELLED: Treatment disparities for disabled Medicare beneficiaries with stage I non-small cell lung cancer.
OBJECTIVE: To compare initial treatment and survival of nonelderly adults with and without disabilities newly diagnosed with non-small cell lung cancer.
DESIGN: Retrospective analyses; population-based cohorts.
SETTING: Eleven Surveillance, Epidemiology, and End Results cancer registries. PARTICIPANTS: Persons with disability Medicare entitlement (n=1016) and nondisabled persons (n=8425) ages 21 to 64 years when diagnosed with stage I, pathologically confirmed, first primary non-small cell lung cancer between January 1, 1988, and December 31, 1999.
INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: Initial cancer treatments (surgery, radiotherapy), survival (through December 31, 2001). Multivariable logistic regression and Cox proportional hazards regression estimated adjusted associations of disability status with treatments and survival.
RESULTS: Persons with disabilities were much more likely to be male, non-Hispanic black, and not currently married. Although 82.2% of nondisabled persons had surgery, 68.5% of disabled persons received operations. Adjusted relative risks (RRs) of receiving surgery were especially low for persons with respiratory disabilities (adjusted RR=.76; 95% confidence interval [CI], .67-.85), nervous system conditions (adjusted RR=.86; 95% CI, .76-.98), and mental health and/or mental retardation disorders (adjusted RR=.92; 95% CI, .86-.99). Persons with disabilities had significantly higher cancer-specific mortality rates (hazard ratio [HR]=1.37; 95% CI, 1.24-1.51) than persons without disabilities. Observed differences in cancer mortality persisted after adjusting for demographic and tumor characteristics (adjusted relative HR=1.23; 95% CI, 1.10-1.39). Further adjustment for surgery use eliminated statistically significant differences in cancer mortality between persons with and without disabilities across disabling conditions.
CONCLUSIONS: Persons with disabilities were much less likely than nondisabled Medicare beneficiaries to receive surgery; statistically significant cancer-specific mortality differences disappeared after accounting for these treatment differences. Future research must explore reasons for these findings and whether survival of disabled Medicare beneficiaries with early-stage, non-small cell lung cancer could improve if surgical treatment disparities were eliminated.

Entities:  

Mesh:

Year:  2008        PMID: 18373987     DOI: 10.1016/j.apmr.2007.09.042

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  16 in total

1.  Disparities in short-term and long-term all-cause mortality among Korean cancer patients with and without preexisting disabilities: a nationwide retrospective cohort study.

Authors:  Sang Min Park; Ki Young Son; Jae-Hyun Park; Belong Cho
Journal:  Support Care Cancer       Date:  2011-04-26       Impact factor: 3.603

2.  End of life and women aging with a disability.

Authors:  Deborah L Volker; Cynthia Zolnierek; Tracie Harrison; Janiece Walker
Journal:  J Palliat Med       Date:  2012-04-26       Impact factor: 2.947

3.  The relation between health insurance and health care disparities among adults with disabilities.

Authors:  Nancy A Miller; Adele Kirk; Michael J Kaiser; Lukas Glos
Journal:  Am J Public Health       Date:  2013-12-12       Impact factor: 9.308

4.  Early stage breast cancer treatments for younger Medicare beneficiaries with different disabilities.

Authors:  Lisa I Iezzoni; Long H Ngo; Donglin Li; Richard G Roetzheim; Reed E Drews; Ellen P McCarthy
Journal:  Health Serv Res       Date:  2008-05-12       Impact factor: 3.402

5.  Disparities in lung cancer staging with positron emission tomography in the Cancer Care Outcomes Research and Surveillance (CanCORS) study.

Authors:  Michael K Gould; Ellen M Schultz; Todd H Wagner; Xiangyan Xu; Sharfun J Ghaus; Robert B Wallace; Dawn Provenzale; David H Au
Journal:  J Thorac Oncol       Date:  2011-05       Impact factor: 15.609

6.  Identifying specific chemotherapeutic agents in Medicare data: a validation study.

Authors:  Jennifer L Lund; Til Stürmer; Linda C Harlan; Hanna K Sanoff; Robert S Sandler; Maurice Alan Brookhart; Joan L Warren
Journal:  Med Care       Date:  2013-05       Impact factor: 2.983

7.  Delay in seeing a doctor due to cost: disparity between older adults with and without disabilities in the United States.

Authors:  Jae Chul Lee; Romana Hasnain-Wynia; Denys T Lau
Journal:  Health Serv Res       Date:  2011-11-08       Impact factor: 3.402

8.  Analyzing excess mortality from cancer among individuals with mental illness.

Authors:  Jackson S Musuuza; Marion E Sherman; Kraig J Knudsen; Helen Anne Sweeney; Carl V Tyler; Siran M Koroukian
Journal:  Cancer       Date:  2013-04-12       Impact factor: 6.860

9.  A double whammy: health promotion among cancer survivors with preexisting functional limitations.

Authors:  Deborah L Volker; Heather Becker; Sook Jung Kang; Vicki Kullberg
Journal:  Oncol Nurs Forum       Date:  2013-01       Impact factor: 2.172

10.  Exploring attitudes about developing cancer among patients with pre-existing mobility disability.

Authors:  Nicole D Agaronnik; Areej El-Jawahri; Lisa I Iezzoni
Journal:  Psychooncology       Date:  2020-10-25       Impact factor: 3.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.